ERVEBO

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, Poland

Active ingredients

The drug ERVEBO contains one active pharmaceutical ingredient (API):

1 Ebola virus, live attenuated UNII P7ZRG1LJ3A - EBOLA VIRUS/H. SAPIENS-TC/COD/1995/KIKWIT-9510622 ENVELOPE GLYCOPROTEIN GENE (VIRAL NEGATIVE STRAND)

Ebola vaccine consists of a live, attenuated recombinant vesicular stomatitis virus-based vector expressing the envelope glycoprotein gene of Zaire Ebola virus (rVSV∆G-ZEBOV-GP). Immunisation of subjects with the vaccine results in an immune response and protection from Zaire Ebola Virus Disease (EVD). Read about Ebola vaccine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ERVEBO Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07BX02		J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BX Other viral vaccines
Discover more medicines within J07BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1806713
Country: FR	Base de données publique des médicaments	Identifier(s): 62614126
Country: IT	Agenzia del Farmaco	Identifier(s): 048364018
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1088943
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100424330